Sinovac Appoints UHY LLP as Independent Auditor to Address NASDAQ Compliance

summarizeSummary

Sinovac Biotech has appointed UHY LLP as its new independent auditor to complete overdue financial audits, a critical step towards meeting SEC and NASDAQ compliance requirements and facilitating trading resumption.

check_boxKey Events

• New Independent Auditor Appointed

  SINOVAC's Audit Committee has approved the engagement of UHY LLP as its independent auditor and registered public accounting firm, effective October 24, 2025.

• Addressing Compliance Requirements

  UHY will audit financial statements for the years ended December 31, 2021 through 2025, including internal control audits, to meet SEC and NASDAQ compliance requirements.

• Aims for Trading Resumption

  This appointment is an important step in the company's commitment to robust financial oversight and transparency, as it continues to work with NASDAQ toward the aim of trading resumption.

• Follows Nasdaq Listing Grant

  This action directly supports the company's recent grant for continued listing by the Nasdaq Hearings Panel, likely fulfilling a condition for that extension.

auto_awesomeAnalysis

This filing announces a critical step for Sinovac Biotech to regain compliance with NASDAQ listing requirements and work towards trading resumption. The appointment of UHY LLP as the independent auditor, effective October 24, 2025, is crucial for auditing overdue financial statements from 2021 through 2025. This action directly addresses the conditions likely imposed by the Nasdaq Hearings Panel, which recently granted the company's request for continued listing, as disclosed in a concurrent filing. Successful completion of these audits is essential for the company to file its Form 20-Fs and 6-Ks and ultimately resume trading.